Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- LDP Lawmakers Call for Environment to Facilitate Vaccine Development
May 20, 2020
- Check Latest Info and Make Careful Decision on Veklury Use: PMDA Review Report
May 19, 2020
- MHLW Panel to Discuss HIF-PH Inhibitors from GSK, Mitsubishi Tanabe on May 29
May 19, 2020
- MHLW Panel to Discuss Orphan Status for 5 Cell and Gene Products
May 19, 2020
- Health Ministers of Japan, China, South Korea Commit to Support WHO on COVID-19, Timely Share Info
May 19, 2020
- Govt Won't Require Fujifilm-Sponsored Trial Data to Approve Avigan for COVID-19: Abe
May 18, 2020
- Novartis’ Tabrecta, Enerzair Up for MHLW Panel Review on May 28
May 15, 2020
- Japan’s First Humira Biosimilar Could Hit Market as Early as November
May 15, 2020
- Japan Poised to Quickly Approve Futhan, Actemra, Ivermectin for COVID-19 If Effective: Abe
May 15, 2020
- 400,000 Antigen Test Kits for COVID-19 to Be Supplied by End of May: Health Minister
May 15, 2020
- Suspected COVID-19 Cases to First Receive Antigen Test, Followed by PCR Test if Result is Negative: Suga
May 15, 2020
- COVID-19 Vaccines Too Could Be Filed without Clinical Trial Data: Official
May 15, 2020
- MHLW Urging Novartis to Ensure Speedy Zolgensma Supplies: Sr. Vice Minister
May 15, 2020
- Coefficients for Cost-Based Pricing Formula Updated: Chuikyo
May 15, 2020
- Chuikyo Members Frown on Zolgensma’s Sakigake Premium; Topic Up for 2022 Pricing Debate
May 14, 2020
- MHLW to Accept Applications for COVID-19 Treatments Without Clinical Trial Data; Avigan, Alvesco, Futhan Might Be Eligible
May 14, 2020
- GCP Inspections Might Be Postponed amid COVID-19 Outbreak: MHLW
May 14, 2020
- Daiichi Sankyo’s Enhertu, Novartis’ Beovu, Novo’s Ozempic OK’ed for Listing on May 20
May 13, 2020
- Japan Regulators Upped Zolgensma Price after Novartis Complaints: Chuikyo Paper
May 13, 2020
- Japan Starts Distributing Veklury with Supply Volume Undisclosed
May 13, 2020
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…